Proton pump inhibitors and diarrhoea related to Clostridium difficile infection in hospitalised patients: A case-control study

Internal Medicine Journal

Volumn 42, Issue 5, 2012, Pages 591-594

  Leonard, A D ^a   Ho, K M ^b,c   Flexman, J ^d  

^a GLENFIELD HOSPITAL   (United Kingdom)

^b ROYAL PERTH HOSPITAL   (Australia)

^c School of Population Health   (United Kingdom)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Acid suppression; Clostridium difficile infection; Proton pump inhibitor; Risk factor

Indexed keywords

PROTON PUMP INHIBITOR;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; AUSTRALIA; CASE CONTROL STUDY; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG USE; FEMALE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DIARRHEA; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES;

EID: 84861433032     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2012.02770.x     Document Type: Article

References (20)

1. Dial S, Delaney JAC, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired. Clostridium difficile-associated disease. JAMA 2005; 294: 2989-95.
2. Oake N, Taljaard M, van Walraven C, Wilson K, Roth V, Forster AJ. The effect of hospital-acquired Clostridium difficile infection on in-hospital mortality. Arch Intern Med 2010; 170: 1804-10.
3. Zilberberg MD, Shorr AF, Kollef MH. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005. Emerg Infect Dis 2008; 14: 929-31.
4. Vaishnavi C. Established and potential risk factors for Clostridium difficile infection. Indian J Med Microbiol 2009; 27: 289-300.
5. Cadle RM, Mansouri MD, Logan N, Kudva DR, Musher DM. Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis. Am J Health Syst Pharm 2007; 64: 2359-63.
6. Aseeri M, Schroeder T, Kramer J, Zackula R. Gastric acid suppression by proton pump inhibitors as a risk factor for clostridium difficile-associated diarrhea in hospitalized patients. Am J Gastroenterol 2008; 103: 2308-13.
7. Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004; 171: 33-8.
8. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007; 102: 2047-56.
9. Lowe DO, Mamdani MM, Kopp A, Low DE, Juurlink DN. Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study. Clin Infect Dis 2006; 43: 1272-6.
10. Debast SB, Vaessen N, Choudry A, Wiegers-Ligtvoet EA, van den Berg RJ, Kuijper EJ. Successful combat of an outbreak due to Clostridium difficile PCR ribotype 027 and recognition of specific risk factors. Clin Microbiol Infect 2009; 15: 427-34.
11. Shah S, Lewis A, Leopold D, Dunstan F, Woodhouse K. Gastric acid suppression does not promote clostridial diarrhoea in the elderly. QJM 2000; 93: 175-81.
12. Howell MD, Novack V, Grgurich P, Soulliard D, Novack L, Pencina M etal. Iatrogenic gastric acid suppression and the risk of nosocomial clostridium difficile infection. Arch Intern Med 2010; 170: 784-90.
13. Nerandzic MM, Pultz MJ, Donskey CJ. Examination of potential mechanisms to explain the association between proton pump inhibitors and clostridium difficile infection. Antimicrob Agents Chemother 2009; 53: 4133-7.
14. Kaunitz JD, Sachs G. Identification of a vanadate-sensitive potassium-dependent proton pump from rabbit colon. J Biol Chem 1986; 261: 14005-10.
15. Hollingworth S, Duncan EL, Martin JH. Marked increase in proton pump inhibitors use in Australia. Pharmacoepidemiol Drug Saf 2010; 19: 1019-24.
16. IMS Health Report. Leading therapy classes by global pharmaceutical sales. 2006 [cited 2011 Feb 14]. Available from URL:
17. Choudhry MN, Soran H, Ziglam HM. Overuse and inappropriate prescribing of proton pump inhibitors in patients with clostridium difficile. QJM 2008; 101: 445-8.
18. Grube RR, May DB. Stress ulcer prophylaxis in hospitalized patients not in intensive care units. Am J Health Syst Pharm 2007; 64: 1396-400.
19. Edwards SJ, Lind T, Lundell L, DAS R. Systematic review: standard- and double-dose proton pump inhibitors for the healing of severe erosive oesophagitis - a mixed treatment comparison of randomized controlled trials. Aliment Pharmacol Ther 2009; 30: 547-56.
20. Rosenbaum PR. Does a dose-response relationship reduce sensitivity to hidden bias? Biostatistics 2003; 4: 1-10.